scholarly journals Stem cell therapies in age-related neurodegenerative diseases and stroke

2017 ◽  
Vol 34 ◽  
pp. 39-50 ◽  
Author(s):  
Yuan Wang ◽  
Xunming Ji ◽  
Rehana K. Leak ◽  
Fenghua Chen ◽  
Guodong Cao
Keyword(s):  
Stem Cell ◽  
Neurodegenerative Diseases ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Age Related

scholarly journals Trends of Stem Cell Therapies in Age-Related Macular Degeneration

2021 ◽  
Vol 10 (8) ◽  
pp. 1785
Author(s):  
Tadao Maeda ◽  
Sunao Sugita ◽  
Yasuo Kurimoto ◽  
Masayo Takahashi
Keyword(s):  
Stem Cells ◽  
Stem Cell ◽  
Macular Degeneration ◽  
Cell Transplantation ◽  
New Technologies ◽  
Retinal Pigment ◽  
Age Related Macular Degeneration ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Age Related

Age-related macular degeneration (AMD) is a highly prevalent irreversible impairment in the elderly population worldwide. Stem cell therapies have been considered potentially viable for treating AMD through the direct replacement of degenerated cells or secretion of trophic factors that facilitate the survival of existing cells. Among them, the safety of pluripotent stem cell-derived retinal pigment epithelial (RPE) cell transplantation against AMD, and some hereditary retinal degenerative diseases, has been discussed to a certain extent in clinical studies of RPE cell transplantation. Preparations are in progress for its clinical application. On the other hand, clinical trials using somatic stem cells are also being conducted, though these had controversial outcomes. Retinal regenerative medicine using stem cells is expected to make steady progress toward practical use while new technologies are incorporated from various fields, thereby making the role of ophthalmologists in this field increasingly important.

Development of human embryonic stem cell therapies for age-related macular degeneration

2013 ◽  
Vol 36 (7) ◽  
pp. 385-395 ◽  
Author(s):  
Amanda-Jayne F. Carr ◽  
Matthew J.K. Smart ◽  
Conor M. Ramsden ◽  
Michael B. Powner ◽  
Lyndon da Cruz ◽  
...  
Keyword(s):  
Stem Cell ◽  
Embryonic Stem Cell ◽  
Macular Degeneration ◽  
Human Embryonic Stem Cell ◽  
Embryonic Stem ◽  
Age Related Macular Degeneration ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Age Related

Stem Cell Therapies for Blindness due to Corneal, Lens, and Retinal Diseases: A Review

2019 ◽  
Author(s):  
Vincent Gallicchio
Keyword(s):  
Stem Cell ◽  
Age Related Macular Degeneration ◽  
Stem Cell Therapies ◽  
Cell Therapies ◽  
Standard Clinical Practice ◽  
Age Related ◽  
Wide Range ◽  
Corneal Lens ◽  
Cell Sources ◽  
Disease Pathways

Stem cell therapies are continuing to be researched and implemented to treat a wide range of disorders that result in blindness. Major structures of the eye most prevalently tied to blindness are the cornea, lens, and retina, and specific conditions resulting in blindness includes corneal disease, stromal scarring, cataracts, age-related macular degeneration, retinitis pigmentosa, glaucoma, and diabetic retinopathy. This review covers a detailed description of the structures of the eye, the causes and corresponding disease pathways of each form of corneal, lens, and retinal dysfunction that results in blindness, and the current stem cell sources being researched and implemented, through animal models and clinical trials, to treat blindness. The review evaluates the progress of stem cell research and trials and presents the obstacles that remain to be overcome before stem cell sources to treat blindness can become standard clinical practice.

scholarly journals An Overview of Stem Cell Therapies for Parkinson’s Disease

2021 ◽  
Vol 2 (1) ◽  
pp. 143-158
Author(s):  
Sara Faour ◽  
Aarthi Ashok
Keyword(s):  
Parkinson’S Disease ◽  
Stem Cells ◽  
Parkinson's Disease ◽  
Stem Cell ◽  
Cell Therapy ◽  
Neurodegenerative Diseases ◽  
Stem Cell Therapy ◽  
Brain Regions ◽  
Stem Cell Therapies ◽  
Cell Therapies

Parkinson’s disease (PD) is referred to as a neurodegenerative disease which is a disease that targets specific brain regions and is characterized by neuronal death. PD is believed to be caused by the loss of nerve cells in the substantia nigra (SN), a dopamine releasing area (Dickson, 2012). Current treatments are directed at alleviating pain symptoms and slowing down the progression of disease, however, no cure currently exists. Recent advances in stem cell therapies raise new possibilities to treat neurodegenerative diseases. Stem cells have the ability to differentiate into neural cells, and thus, could potentially be used to restore neurogenesis and neuroplasticity (Lunn et al., 2011). There exist several cell types that can be applied in therapy including embryonic stem cells (ESCs), neural stem cells (NSCs), induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs). PD which has localized neural degeneration to the SN may serve as a better model for stem cell therapy and displays greater success when compared to other neurodegenerative diseases that spread to several brain regions (Vasic et al., 2019). This review aims to discuss the several approaches used in stem cell therapy as well as the current challenges and shortcomings of this cell-based therapy.

Sign in / Sign up

Export Citation Format

Share Document